The Wall Street Journal: Celgene said to be near $7 billion deal to buy Impact Biomedicines

Celgene Corp. is nearing a deal to buy biotechnology company Impact Biomedicines for as much as $ 7 billion, according to people familiar with the matter.

The potential deal, which could be announced Monday, calls for Celgene CELG, -1.58%   to buy the privately held San Diego company in three stages, the people said. First there would be an upfront payment of about $ 1 billion, with the next two stages dependent on an approval of Impact’s blood-disease drug from the Food and Drug Administration and successful commercialization, the people said.

Should the drug pan out as hoped, the deal could be worth about $ 7 billion in total.

Celgene, based in Summit, N.J., is one of the biggest U.S. biotechcompanies. It is known for its cancer-drug portfolio but has been trying to diversify beyond its top-selling product, multiple myeloma drug Revlimid, and move into immune disorders like the skin condition psoriasis.

An expanded version of this report appears on

Also popular on

Pfizer ends hunt for drugs to treat Alzheimer’s and Parkinson’s.

Does music help you fall asleep? – Top Stories

You may also like...